JUBLPHARMA
Jubilant Pharmova Limited (JUBLPHARMA) Stock Analysis
Jubilant Pharmova Limited focuses on radiopharmaceuticals, contract research, and generic APIs with global reach. It serves hospitals and innovators in nuclear medicine and CDMO services. The company combines niche pharma and services models. It is a listed pharma and services company.
Healthcare › Drug Manufacturers - Specialty & Generic
₹966.00
+3.23% 1W | -17.20% 52W
Market Cap
15.3k CR
P/E Ratio
43.6
52W High
₹1162
52W Low
₹786
Div. Yield
0.52%
Beta
0.5
50 DMA
₹975.6
200 DMA
₹941
Profit Margin
4.1%
Inst. Own.
23.7%
📊 ANALYZING TREND
⚡ APPROACHING SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,587 | 1,680 | 1,677 | 1,759 | 1,732 | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,122 | 2,290 | 2,229 |
| Expenses | 1,419 | 1,438 | 1,459 | 1,487 | 1,480 | 1,463 | 1,535 | 1,584 | 1,611 | 1,625 | 1,833 | 1,951 | 1,981 |
| Operating Profit | 168 | 242 | 218 | 271 | 252 | 289 | 287 | 345 | 290 | 341 | 289 | 339 | 248 |
| OPM % | 11% | 14% | 13% | 15% | 15% | 17% | 16% | 18% | 15% | 17% | 14% | 15% | 11% |
| Other Income | 9 | 19 | 49 | -151 | 410 | 8 | -10 | 9 | 12 | 4 | -19 | 10 | 20 |
| Interest | 62 | 66 | 71 | 73 | 71 | 61 | 56 | 53 | 49 | 50 | 56 | 56 | 54 |
| Depreciation | 90 | 97 | 95 | 101 | 91 | 91 | 91 | 95 | 98 | 105 | 121 | 117 | 127 |
| Profit before tax | 25 | 98 | 101 | -54 | 500 | 144 | 130 | 206 | 154 | 190 | 93 | 176 | 86 |
| Tax % | 76% | 37% | 34% | 15% | 4% | 29% | 23% | 27% | 34% | 37% | 40% | 32% | 35% |
| Net Profit | 6 | 62 | 66 | -62 | 482 | 102 | 101 | 151 | 102 | 120 | 56 | 119 | 56 |
| EPS in Rs | 0.40 | 3.92 | 4.19 | -3.68 | 30.26 | 6.45 | 6.33 | 9.64 | 6.46 | 7.55 | 3.51 | 7.50 | 3.55 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,751 | 5,749 | 5,861 | 7,518 | 9,111 | 5,976 | 6,099 | 6,130 | 6,282 | 6,703 | 7,234 | 8,280 | 8,608 |
| Expenses | 5,141 | 4,493 | 4,510 | 5,995 | 7,367 | 4,428 | 4,695 | 4,980 | 5,503 | 5,802 | 6,061 | 7,020 | 7,390 |
| Operating Profit | 610 | 1,256 | 1,352 | 1,522 | 1,744 | 1,548 | 1,403 | 1,150 | 779 | 901 | 1,173 | 1,260 | 1,218 |
| OPM % | 11% | 22% | 23% | 20% | 19% | 26% | 23% | 19% | 12% | 13% | 16% | 15% | 14% |
| Other Income | 86 | 4 | 19 | 36 | -249 | 225 | 263 | 8 | -9 | -76 | 416 | 7 | 15 |
| Interest | 368 | 371 | 341 | 284 | 220 | 200 | 184 | 145 | 188 | 272 | 240 | 212 | 217 |
| Depreciation | 288 | 347 | 291 | 415 | 371 | 340 | 349 | 382 | 554 | 382 | 369 | 440 | 470 |
| Profit before tax | 40 | 542 | 738 | 859 | 904 | 1,233 | 1,133 | 630 | 28 | 170 | 981 | 614 | 546 |
| Tax % | 200% | 29% | 22% | 26% | 36% | 27% | 26% | 34% | 333% | 57% | 15% | 35% | |
| Net Profit | -40 | 387 | 575 | 634 | 577 | 898 | 836 | 413 | -65 | 73 | 836 | 398 | 351 |
| EPS in Rs | -3.63 | 24.60 | 36.14 | 40.35 | 36.06 | 56.39 | 52.47 | 25.98 | -3.83 | 4.84 | 52.69 | 25.02 | 22.11 |
| Dividend Payout % | -83% | 12% | 8% | 7% | 12% | 9% | 10% | 19% | -130% | 102% | 9% | 20% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 10.0% | 6.0% | 4.0% |
| Profit CAGR | 47.0% | -13.0% | 1.0% |
Shareholding Pattern
Promoters47.67%
FIIs17.40%
DIIs9.52%
Public24.83%
Promoters47.67%
FIIs16.56%
DIIs10.53%
Public24.60%
Promoters47.67%
FIIs15.96%
DIIs11.23%
Public24.57%
Promoters47.67%
FIIs15.90%
DIIs11.63%
Public24.25%
Promoters47.67%
FIIs15.87%
DIIs12.40%
Public23.50%
Promoters50.67%
FIIs23.22%
DIIs1.62%
Public23.11%
Promoters50.67%
FIIs19.06%
DIIs3.77%
Public25.91%
Promoters50.67%
FIIs17.23%
DIIs7.05%
Public24.48%
Promoters47.67%
FIIs15.90%
DIIs11.63%
Public24.25%
Promoters47.67%
FIIs15.87%
DIIs12.40%
Public23.50%
JUBLPHARMA
Holdings Analysis
Key strengths & risk signals
55
Overall
47
Fundamental
64
Technical
Risks (3)
Cannot calculate PEG - insufficient growth data.
RECOVERY MODE! Current price (966.0) above 200-day but below 50-day.
WEAK YEAR! Stock declined 17.2% in the last year.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (975.6) is above 200-day average (941.0) - positive signal.
LOW VOLATILITY! Beta of 0.50 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 365,639 vs down days: 289,308. Ratio: 1.26x
Fundamental & Technical Analysis
55Overall
47Fundamental
64Technical
Fundamental Breakdown
Growth Quality
10/30
Revenue CAGR: 9.8% (MODERATE, 8/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! 4.1% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.52% yield - little to no income.
Debt to Equity
8/10
LOW DEBT! D/E of 0.44 - strong balance sheet.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 23.91% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
10/10
BULLISH TREND! 50-day average (975.6) is above 200-day average (941.0) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (966.0) above 200-day but below 50-day.
Trend Pattern
10/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
2/10
WEAK YEAR! Stock declined 17.2% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 365,639 vs down days: 289,308. Ratio: 1.26x
RSI
3/5
NEUTRAL! RSI at 48.7 - balanced momentum.
52W Range
3/5
MID RANGE! Trading at 47.9% of 52W range - neutral zone.
Momentum
4/5
GOOD MOMENTUM! Price has grown across all timeframes - up 3.2% (1 week), 3.7% (1 month), 0.1% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.50 - stable stock, less market risk.
JUBLPHARMA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-27 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JUBLPHARMA | ₹966.00 | 43.6 | 4.1% | 9.8% | – | -17.2% | 55 | APPROACHING SUPPORT | -45.1% | -52.7% | +18.2% | -2.2% |
| NATCOPHARM | ₹804.40 | 12.7 | 32.8% | 14.5% | 25.6% | +0.8% | 69 | CONSOLIDATING DOWN | -57.0% | -22.9% | -44.7% | -0.5% |
| ASTRAZEN | ₹6,514.50 | 91.6 | 6.8% | 31.3% | 23.6% | -28.7% | 67 | BOUNCE FROM SUPPORT | +14.9% | +64.4% | +30.4% | +6.8% |
| SUDEEPPHRM | ₹1,210.30 | 71.8 | 26.5% | 14.4% | 40.5% | +56.6% | 78 | BREAKDOWN | +12.7% | +26.8% | +20.9% | +24.3% |
| COHANCE | ₹443.60 | 372.8 | 5.0% | 18.3% | -24.2% | -37.3% | 60 | APPROACHING SUPPORT | -79.5% | -163.1% | -14.2% | +12.9% |
| ERIS | ₹1,261.60 | 24.5 | 21.4% | 23.3% | 17.5% | -21.3% | 70 | BOUNCE FROM SUPPORT | +52.9% | +29.1% | +12.6% | +2.4% |
| ALIVUS | ₹1,474.40 | 27.1 | 24.9% | 6.9% | 6.5% | +69.3% | 82 | BREAKOUT | – | +22.9% | – | +6.5% |
| SHILPAMED | ₹933.90 | 54.7 | 18.0% | 13.8% | – | +149.2% | 67 | BOUNCE FROM SUPPORT | +79.6% | -21.5% | +43.0% | +13.6% |
Data from TradeAlone · Updated daily
JUBLPHARMA News
